Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine
Clin. transl. oncol. (Print)
; 12(6): 450-452, jun. 2010. ilus
Artigo
em Inglês
| IBECS
| ID: ibc-124096
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
Gemcitabine is indicated for the treatment of nonmicrocytic lung, breast, pancreatic, bladder and ovarian cancer. Mild dyspnea has been reported but the incidence of severe lung damage is low. We report the case of a 58-year-old woman diagnosed with locally advanced infiltrating ductal carcinoma of the breast who received gemcitabine as part of neoadjuvant chemotherapy and suffered from severe pulmonary toxicity. We reviewed the cases published in the literature and conclude that although Gemcitabine is generally well tolerated, pulmonary toxicity requires high level of suspicion and prompt treatment to prevent an unfavourable outcome (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Neoplasias da Mama
/
Carcinoma
/
Antineoplásicos
Limite:
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2010
Tipo de documento:
Artigo
Instituição/País de afiliação:
A Coruña University Hospital/Spain
/
Ferrol Hospital/Spain